Left Bundle-Branch Pacing versus Right Ventricular Pacing for Atrioventricular Block
Source: View publication →
In patients with atrioventricular block, left bundle-branch pacing significantly reduced the composite risk of death, heart failure hospitalization, or pacing-induced cardiomyopathy compared to traditional right ventricular pacing.
Key Findings
Study Design
Study Limitations
Clinical Significance
The OptimPacing trial provides landmark randomized evidence that conduction system pacing—specifically left bundle-branch pacing—prevents the electrical and mechanical dyssynchrony typically caused by standard right ventricular pacing. By demonstrating a near elimination of pacing-induced cardiomyopathy (0% vs 11.7%) in a population requiring a heavy pacing burden, these data strongly support a paradigm shift toward making LBBP the default, standard-of-care pacing strategy for patients with atrioventricular block and normal baseline cardiac function.
Historical Context
For decades, the standard treatment for atrioventricular block has been right ventricular (RV) pacing. While life-saving and highly reliable, pacing the right ventricle creates an artificial left bundle branch block pattern. Over time, this electrical dyssynchrony can lead to mechanical dyssynchrony, left ventricular adverse remodeling, and pacing-induced cardiomyopathy, particularly in patients with a high pacing burden. His-bundle pacing emerged as a physiological alternative but suffered from high capture thresholds, sensing issues, and technically challenging lead placements. Left bundle-branch pacing (LBBP) was recently pioneered to bypass the site of block while providing a wider target and better electrical parameters. OptimPacing serves as a definitive trial validating the long-term clinical superiority of LBBP over RV pacing.
Guided Discussion
High-yield insights from every perspective
How does traditional right ventricular pacing lead to pacing-induced cardiomyopathy, and anatomically, why does left bundle-branch pacing (LBBP) mitigate this risk?
Key Response
Right ventricular pacing creates an artificial left bundle branch block pattern, causing mechanical dyssynchrony. The right ventricle contracts before the left, leading to adverse remodeling, cellular-level alterations in calcium handling, and eventually a decreased ejection fraction (pacing-induced cardiomyopathy). LBBP directly stimulates the left conduction system deep in the interventricular septum, resulting in rapid, synchronous left ventricular activation that preserves physiological ventricular mechanics.
A 65-year-old patient with complete heart block requires a pacemaker. Based on recent data comparing LBBP to RVP, which patient factors would most strongly favor attempting LBBP as the initial strategy rather than standard right ventricular pacing?
Key Response
Patients with an expected high ventricular pacing burden (e.g., >20%), baseline mild-to-moderate left ventricular dysfunction (EF 36-50%), or pre-existing heart failure are at the highest risk for pacing-induced cardiomyopathy with standard RVP. In these populations, LBBP is strongly favored to prevent clinical deterioration, heart failure hospitalization, and adverse remodeling.
While LBBP shows superiority over RVP in preventing pacing-induced cardiomyopathy, what are the specific procedural challenges, anatomical pitfalls, and potential unique long-term complications of deep septal lead deployment compared to traditional RV apical leads?
Key Response
LBBP requires driving the lead deep into the interventricular septum to capture the left bundle. Procedural challenges include the risk of septal perforation into the left ventricle, damage to septal coronary arteries, and a steeper learning curve for delivery sheath manipulation. Long-term concerns include questions about lead extractability, the potential for late septal mechanical damage, and capture threshold rises, which demand nuanced patient selection and meticulous follow-up.
Given the significant reduction in the composite risk of death, HF hospitalization, or pacing-induced cardiomyopathy with LBBP, should we abandon traditional RVP entirely for AV block, or are there still distinct clinical scenarios where RVP remains the standard of care?
Key Response
While LBBP is superior for patients needing a high ventricular pacing burden, RVP remains appropriate and often preferred for patients with expected infrequent pacing (e.g., intermittent sinus node dysfunction without AV block), those with extreme frailty or limited life expectancy where procedural time and risk must be minimized, or in cases of challenging right-sided anatomy where deep septal penetration is unfeasible or carries unacceptable perforation risk.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The trial utilizes a composite primary endpoint of death, heart failure hospitalization, or pacing-induced cardiomyopathy. How might the inclusion of a surrogate echocardiographic outcome alongside hard clinical outcomes bias the interpretation of the treatment effect, and how should competing risks be modeled in this statistical context?
Key Response
Combining a surrogate imaging endpoint (PICM) with mortality and HF hospitalization can inflate the apparent treatment effect if the event rate is primarily driven by the surrogate rather than hard clinical outcomes. Furthermore, mortality acts as a competing risk for developing PICM; a rigorous statistical approach must employ Fine-Gray subdistribution hazard models or similar competing risk frameworks to ensure the reduction in PICM is not merely an artifact of differential mortality or unequal follow-up duration between the study arms.
In a randomized trial of LBBP versus RVP, blinding the treating physicians and patients is virtually impossible due to distinct ECG morphologies. What specific blinded adjudication processes and missing data handling strategies must be detailed in the manuscript to convince a peer reviewer that the primary outcome results are free from ascertainment bias?
Key Response
Because the pacing modality is obvious on an ECG (narrow/pseudo-RBBB vs. wide QRS LBBB pattern), unblinded clinicians might have a lower threshold to admit RVP patients for heart failure or alter medical therapy. A robust trial must use a blinded Clinical Events Committee to adjudicate HF hospitalizations and a blinded core lab for serial echocardiographic evaluation of PICM. Additionally, the handling of crossover (e.g., failed LBBP converted to RVP) must be strictly analyzed via intention-to-treat to prevent bias favoring the intervention arm.
Current ACC/AHA/HRS and ESC guidelines give conduction system pacing a Class IIa/IIb recommendation for AV block patients with an anticipated high pacing burden. Does the evidence from this trial justify elevating LBBP to a Class I recommendation for all patients with AV block, and how does this affect the strength of recommendation for baseline normal versus reduced ejection fraction subgroups?
Key Response
If this trial demonstrates a robust, generalizable reduction in hard clinical outcomes across all EF strata, it could compel guidelines to upgrade LBBP (or conduction system pacing broadly) to a Class I (Level of Evidence: B-R or A) recommendation for patients with expected >20% pacing. However, if the benefit is predominantly driven by patients with borderline or reduced baseline EF (36-50%), the Class I recommendation might remain restricted to that specific subgroup, leaving LBBP as a Class IIa alternative to RVP for patients with strictly normal baseline left ventricular function.
Clinical Landscape
Noteworthy Related Trials
DAVID Trial
Tested
Dual-chamber pacing (DDDR) at 70 bpm
Population
Patients with standard indications for an ICD and no indication for antibradycardia pacing
Comparator
Ventricular backup pacing (VVI) at 40 bpm
Endpoint
Composite of time to death or first hospitalization for congestive heart failure
BLOCK HF Trial
Tested
Biventricular pacing
Population
Patients with AV block and left ventricular systolic dysfunction
Comparator
Right ventricular pacing
Endpoint
Composite of death, heart failure urgent care visit, or adverse LV remodeling
His-SYNC Trial
Tested
His-bundle pacing
Population
Patients with heart failure meeting indications for cardiac resynchronization therapy
Comparator
Biventricular pacing
Endpoint
Improvement in QRS duration and left ventricular ejection fraction at 6 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis